• Good News for Drinking Water – US Nuclear Corp

    Good News for Drinking Water

    Independent Test Lab Evaluates Instrumentation for Detecting Radiation in Drinking Water

    Since 9/11 and there are still holes in the security of the nation’s infrastructure, particularly for drinking water.  This security deficit is currently being addressed in some community water systems with water monitoring instruments.

    Read More

  • The Desperate Need For Medical Isotopes

    The Desperate Need For Medical Isotopes

    The Desperate Need For Medical Isotopes

    Los Angeles, CA. March 18, 2019 – With preparations underway for manufacturing the MIFTEC Z-pinch (ZEBRA) Fusion Medical Isotope Generators, US Nuclear Corp. (OTCBB: UCLE) is one step closer to ending the dire worldwide shortage of medical isotopes.  The federal government is so desperate to find a domestic, stable supply of medical isotopes that they recently awarded over $60 million in funding to 8 projects/companies working on solutions for this demand.  Of these 8 companies, only 3 have timelines to supply medical isotopes in the near future, and of those 3, Magneto-Inertial Fusion Technologies, Inc (MIFTI, parent company to MIFTEC) has the most promising solution.  MIFTEC’s patented fusion-powered medical isotope generator can not only solve the medical isotope shortage, but the revolutionary process also offers numerous advantages to current production methods, including:

    • MIFTEC’s process is fueled by a simple isotope of hydrogen from a renewable source: seawater.
      Current production methods of medical isotopes are fission-based nuclear reactors or accelerators that require either highly enriched or low enriched uranium (HEU/LEU) to operate. These methods are costly, multi-step processes that result in nuclear waste byproducts that must be safely contained and stored for hundreds of years while being protected from theft by terrorists.
    • Due to the eco-friendly, fusion-based technology, the capital and operational costs are a fraction of that for fission or accelerator technology.  Additionally, medical isotope production costs are up to 50% less than all other current manufacturing processes.
    • The device is designed to fit into most hospitals, nuclear medicine clinics, and laboratories.  It is ideal for local, domestic production, and results in a major reduction in transportation and import costs.  Local production also solves the timeline issues of Mo-99’s 66-hour half-life.
    • No production limit problem.  Current methods to build a nuclear reactor or accelerator are time-consuming and expensive, and once finally built, these facilities have a maximum production limit.  There is currently around a $5 billion shortfall in medical isotope production. US Nuclear can build MIFTEC’s medical isotope generators in a fraction of the time and cost, with the production line continuing until demand has been filled.

    Safe Harbor Act

    This press release includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Actual results may differ from expectations, estimates, and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results.

    Investors may find additional information regarding US Nuclear Corp. at the SEC website at http://www.sec.gov, or the company’s website at https://www.usnuclearcorp.com


    US Nuclear Corp. (UCLE)
    Robert I. Goldstein, President, CEO, and Chairman
    Rachel Boulds, Chief Financial Officer
    (818) 883 7043
    Email: info@usnuclearcorp.com

    Yahoo Finance

  • Carbon 14 Major Power Industry Pollutant

    Environmental scientists have identified Carbon 14, better known as C14, as a major radiological pollutant and a serious health hazard. Emitted from both coal-fired and nuclear power plants these contaminants have only recently been identified as a major cause of radiation exposure to the general public in proximity to these power plants.  Additionally, some hospitals, universities, and pharmacology companies also emit these radionuclides.

    Read More

  • US Nuclear/FlyCam Sells Fleet of DroneRads to Saudi Arabia Civil Defense

    US Nuclear/Flycam Sells Fleet of Drone-Rads to Saudi Arabia Civil Defense

    US Nuclear/FlyCam Sells Fleet of DroneRads to Saudi Arabia Civil Defense

    Los Angeles, CA. January 23, 2019 – US Nuclear Corp. (OTCBB: UCLE) is proud to announce that it has sold a fleet of DroneRAD systems to the Saudi Arabia Civil Defense.  This order brings US Nuclear’s current order backlog to the $2,000,000 range. The DroneRAD is aerial radiation and chemical detection system which utilizes the revolutionary Neo and Zoe drones offered by FlyCAM UAV. These aerial platforms are rugged, robust, weatherproof, and can withstand high winds up to 35 knots (40 mph) and temperature extremes (-10°C / 13°F) without compromising flight capabilities. The DroneRADwill be used by the Saudi Arabia Civil Defense for national security purposes.

    The DroneRAD sensor system is designed for both radiation and chemical detection and is highly sensitive and durable even in hostile environmental conditions. Several different sensor packages are available that range from conducting neutron or gamma surveys, to measuring airborne particulates and chemical contaminants.


  • US Nuclear Reports 3rd Quarter 2018 Results – 35.6% Increase in Revenue

    US Nuclear Reports 3rd Quarter 2018 Results – 35.6% Increase in Revenue

    Los Angeles, CA. November 20, 2018 – US Nuclear Corp. (OTCBB: UCLE)

    • Sales for the three months ended September 30, 2018, were $1,145,480, an increase of 35.6% for the same period in 2017
    • Gross profit was $512,096, an increase of 34% for the same period in 2017
    • During the three months ended September 30, 2018, the company entered into an agreement with MIFTEC and paid $1,084,000 for certain manufacturing and supply rights as discussed below
    • Net loss from operations ($1,414,715) due to stock-based compensation and acquisition of manufacturing and supply rights offset by an increase in gross profits due to higher sales (more…)